Esperion Therapeutics Balance Sheet - Quarterly (NASDAQ:ESPR)

Add to My Stocks
$49.31 $0.06 (0.12%) ESPR stock closing price Sep 22, 2017 (Closing)

The financial analysis of a company like Esperion Therapeutics involves checking the three financial statements of the company in detail, of which the balance sheet is one. How cash on hand has increased or decreased is one of the many indicators used while undertaking the Esperion Therapeutics stock analysis, and provides insights into the firm's financial performance. Good quarterly results indicate a company's strong financial performance. Its important to check all financial statements including the balance sheet. View Esperion Therapeutics quarterly results to get the balance sheet details for the latest 40 quarters data.

show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec.2017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q32015 Q22015 Q1
Marketable Securities147.03M162.01M173.41M162.96M158.41M157.26M134.92M134.77M94.99M69.46M
Raw Materials----------
Work In Progress----------
Finished Goods----------
Notes Receivable----------
Other Current Assets3.54M6.12M1.99M3.36M1.91M2.58M2.13M3.24M0.93M1.71M
Esperion Therapeutics Total Current Assets
Property Plant & Equipment--1.28M---1.16M---
Accumulated Depreciation--0.6M---0.35M---
Esperion Therapeutics Net Property Plant & Equipment
Investment & Advances13.68M25.92M30.9M49.64M67.63M88.18M80.31M86.77M89.5M44.61M
Other Non-Current Assets----------
Deferred Charges----------
Deposits & Other Assets----------
Esperion Therapeutics Total Assets
Notes Payable----------
Accounts Payable18.71M11.63M4.59M1.78M1.56M1.54M0.7M1.97M3.3M2.89M
Current Portion Long-Term Debt1.76M1.73M1.7M1.68M1.65M1.62M1.6M1.57M1.42M1.03M
Current Portion Capital Leases----------
Accrued Expenses10.51M8.23M9.28M4.69M4.41M2.82M3.31M3.27M2.29M3.01M
Income Taxes Payable----------
Other Current Liabilities----------
Esperion Therapeutics Total Current Liabilities
Deferred Taxes/Income----------
Convertible Debt----------
Long-Term Debt0.14M0.58M1.02M1.45M1.87M2.28M2.68M3.08M3.47M3.85M
Non-Current Capital Leases----------
Other Long-Term Liabilities----------
Esperion Therapeutics Total Liabilities
Minority Interest----------
Preferred Stock----------
Common Stock Net0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M
Capital Surplus467.5M462.47M457.95M454.37M450.66M446.52M441.94M437.54M433.79M430.34M
Retained Earnings-313.18M-269.84M-229.2M-200.24M-182.84M-168.8M-154.22M-141.1M-128.29M-115.9M
Treasury Stock----------
Other Liabilities-0.23M-0.22M-0.17M0.02M0.11M0.01M-0.48M0.01M-0.06M-0.03M
Esperion Therapeutics Shareholders Equity
Esperion Therapeutics Total Liabilities & Shareholders Equity
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Looking at Esperion Therapeutics historical stock prices and the current Esperion Therapeutics stock price can tell you how the stock price has moved, whereas the Esperion Therapeutics PE ratio chart shows if its shares are overpriced in comparison to peers. The important things to look for in a balance sheet are:
  • Assets: ESPR total assets, which was at $185.24M for 2017-Q2 is a balance sheet item representing value of what Esperion Therapeutics owns. Assets are brought to aid a firms operations, or to increase its economic value. It must be noted that tech stocks may not have a lot of assets, as the value for these companies is often derived from future earning potential.
  • Liabilities include short term loans and long term loans availed by the company to fund its business operations. ESPR stock had total liabilities of $31.13M for quarter 2017-Q2.

Esperion Therapeutics Balance Sheet - Key Ratios